← Trials/Trial dossier/NCT06889454
Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS
The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome
Lead sponsor
Asset
GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
1
Enrollment
120
estimated
Study population
PCOS
Key I/E criterion
•Female
Primary endpoints
•Τhe change in Global Longitudinal Strain during Oral glucose Tolerance Test•Pulse Wave Velocity during Oral glucose Tolerance Test•Perfused Boundary Region during Oral glucose Tolerance Test
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
Women with PCOS
Inclusion criteria
1. Age > 16 years old
2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:
3. Absence of treatment for PCOS the last six months
4. Patients who have the ability to understand and sign the consent form.
Exclusion criteria
1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone [17-OHP]), Cushing syndrome, acromegaly
2. Treatment with contraceptive or metformin
3. Type 2 diabetes mellitus
4. Treatment for diabetes
5. Pregnancy
6. Lactation
7. Malignancy
Endpoints (11)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Cardiometabolic biomarkers
7 endpointsThe change in Pulse Wave Velocity during Oral glucose Tolerance Test
Time frame:120minute of Oral glucose Tolerance Test
change from baseline, improvement
The change in Pulse Wave Velocity
Time frame:six months
change from baseline, improvement
The change in Metalloproteinase 9
Time frame:six months
change from baseline, improvement
Τhe change in Coronary flow reserve during Oral glucose Tolerance Test
Time frame:120 min of Oral glucose Tolerance Test
change from baseline, improvement
Τhe change in Flow mediated Dilation during Oral glucose Tolerance Test
Time frame:120min of Oral glucose Tolerance Test
change from baseline, improvement
The change in Coronary flow reserve
Time frame:six months
change from baseline, improvement
The change in Flow mediated Dilation
Time frame:six months
change from baseline, improvement
Other (unclassified)
4 endpointsΤhe change in Global Longitudinal Strain during Oral glucose Tolerance Test
Time frame:120 minute of Oral glucose Tolerance Test
change from baseline, improvement
The change in Perfused Boundary Region during Oral glucose Tolerance Test
Time frame:120minute of Oral glucose Tolerance Test
change from baseline, descriptive
The change in Global Longitudinal Strain
Time frame:six months
change from baseline, improvement
The change in Perfused Boundary Region
Time frame:six months
change from baseline, descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.